Wugen

Wugen company information, Employees & Contact Information

Explore related pages

Related company profiles:

Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. Wugen is based out of St. Louis, Missouri and San Diego, California.

Company Details

Employees
66
Founded
-
Address
4260 Forest Park Ave,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
wugen.com
HQ
St. Louis, Missouri
Looking for a particular Wugen employee's phone or email?

Wugen Questions

News

Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007 - GlobeNewswire

Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007 GlobeNewswire

Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T - BioPharma Dive

Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T BioPharma Dive

Wugen raises $115m for trial of T-cell cancer therapy - Clinical Trials Arena

Wugen raises $115m for trial of T-cell cancer therapy Clinical Trials Arena

$115 Million Biotech Deal: Wugen's Off-the-Shelf CAR-T Cell Therapy Gets Major Fidelity Backing - Stock Titan

$115 Million Biotech Deal: Wugen's Off-the-Shelf CAR-T Cell Therapy Gets Major Fidelity Backing Stock Titan

Wugen woos VCs, landing $115M to bring fratricide-resistant CAR-T cell therapy to market - Fierce Biotech

Wugen woos VCs, landing $115M to bring fratricide-resistant CAR-T cell therapy to market Fierce Biotech

Wugen Raises $115M in Funding - FinSMEs

Wugen Raises $115M in Funding FinSMEs

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing - GlobeNewswire

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing GlobeNewswire

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June - Yahoo Finance

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June Yahoo Finance

Wugen Announces Dosing of First Patients in Pivotal Trial - GlobeNewswire

Wugen Announces Dosing of First Patients in Pivotal Trial GlobeNewswire

Wugen’s T-cell fundraiser | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Wugen’s T-cell fundraiser | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen's Off-the-shelf CAR-T Cellular Therapies - PR Newswire

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen's Off-the-shelf CAR-T Cellular Therapies PR Newswire

Wugen nabs $115M for pivotal study of allogeneic CAR-T - FirstWord Pharma

Wugen nabs $115M for pivotal study of allogeneic CAR-T FirstWord Pharma

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies - BioInformant

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies BioInformant

Biotech firm Wugen raises $115M to advance rare cancer drug treatment - The Business Journals

Biotech firm Wugen raises $115M to advance rare cancer drug treatment The Business Journals

Wugen secures $115 million to advance WU-CART-007 - The Pharma Letter

Wugen secures $115 million to advance WU-CART-007 The Pharma Letter

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL - OncLive

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL OncLive

Wugen doses first patient in AML therapy trial - Clinical Trials Arena

Wugen doses first patient in AML therapy trial Clinical Trials Arena

Wugen to Initiate a Pivotal Trial for Its Investigational, - GlobeNewswire

Wugen to Initiate a Pivotal Trial for Its Investigational, GlobeNewswire

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical - GlobeNewswire

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical GlobeNewswire

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid C - GlobeNewswire

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid C GlobeNewswire

Wugen Appoints Mark Alles As Chair - citybiz

Wugen Appoints Mark Alles As Chair citybiz

Wugen secures $115 million in equity financing led by Fidelity - Investing.com

Wugen secures $115 million in equity financing led by Fidelity Investing.com

The Week’s 10 Biggest Funding Rounds: Commonwealth Fusion’s Giant Financing Leads Otherwise Slow Week For Big Deals - Crunchbase News

The Week’s 10 Biggest Funding Rounds: Commonwealth Fusion’s Giant Financing Leads Otherwise Slow Week For Big Deals Crunchbase News

Exclusive: Shinobi raises $51M to take on cell therapy challenges with ex-Wugen CEO at helm, Carl June in support - Endpoints News

Exclusive: Shinobi raises $51M to take on cell therapy challenges with ex-Wugen CEO at helm, Carl June in support Endpoints News

New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff - Fierce Biotech

New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff Fierce Biotech

A cancer drug startup banks new funds for NK cell therapy - BioPharma Dive

A cancer drug startup banks new funds for NK cell therapy BioPharma Dive

HCW Biologics congratulates Wugen on equity financing - TipRanks

HCW Biologics congratulates Wugen on equity financing TipRanks

High-profile St. Louis startup relocates HQ to larger Cortex space where it could double its workforce - KSDK

High-profile St. Louis startup relocates HQ to larger Cortex space where it could double its workforce KSDK

St. Louis cancer drug startup hires exec with experience taking firms public - The Business Journals

St. Louis cancer drug startup hires exec with experience taking firms public The Business Journals

Wugen raises $172m to develop promising off-the-shelf NK cell therapies - Clinical Trials Arena

Wugen raises $172m to develop promising off-the-shelf NK cell therapies Clinical Trials Arena

St. Louis-based cancer drug startup Wugen names new CEO - The Business Journals

St. Louis-based cancer drug startup Wugen names new CEO The Business Journals

High-profile St. Louis startup opens new headquarters in Cortex (Photos) - The Business Journals

High-profile St. Louis startup opens new headquarters in Cortex (Photos) The Business Journals

Top Wugen Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant